Comment and reply on: The cost-effectiveness of palivizumab for respiratory syncytial virus prophylaxis in premature infants with a gestational age of 32-35 weeks: a Canadian-based analysis.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples